Abstract:AL amyloid cardiomyopathy is characterized by the deposition of amyloid fibers from monoclonal immunoglobulin light chain proteins (AL-LC) in the heart. We and others have shown that AL-LC directly results in cardiac toxicity; however, the mechanisms underlying this toxicity remain to be determined. Morphological examinations of hearts from patients with AL amyloid cardiomyopathy reveal increased double membrane autophagosome-like structures and mitochondrial deformation. Using isolated adult rat cardiomyocytes, we therefore examined whether dysregulated autophagy mediates the development of AL-LC induced cardiac toxicity. Methods and Results: Autophagy is a dynamic process and autophagic flux is, hence, determined by measurement of LC3-II protein expression in the absence and presence of lysosome inhibitors (E64d and pepstatin A). The autophagic substrate, polyubiquitin-binding protein (p62), was also examined via immunoblotting. We found that LC3-II expression increased in the absence but decreased in the presence of lysosome inhibitors in cardiomyocytes exposed to AL-LC relative to vehicle control. Moreover, p62 expression was increased in AL-LC treated cardiomyocytes, suggesting that AL-LC resulted in impaired clearance of autophagosomes in cardiomyocytes. To define the causal relationship between dysregulated autophagic clearance and AL-LC induced cardiac toxicity, we determined the functional consequences of autophagic inhibition by treatment with 3MA (3-Methyladenine, PI3K inhibitor), or autophagic activation by treatment with rapamycin (mTOR inhibitor). Inhibition of autophagy led to worsen of AL-LC induced cardiac toxicity whereas activation of autophagy protected cardiomyocytes against AL-LC induced cardiac toxicity, as measured by ROS production and cell death. Conclusion: Our data demonstrate that AL-LC directly results in impaired autophagic clearance in cardiomyocytes, contributing to the development of amyloid cardiac toxicity and cardiomyopathy. Therapies aimed at modulation of cellular autophagy may provide new treatment approaches for patients with AL amyloid cardiomyopathy.

Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis

Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis

Abstract 18695: Role of Autophagy in Amyloidogenic Light Chain Induced Cardiac Toxicity

Cryo-EM reveals that cardiac IGLV6-derived AL fibrils can be polymorphic

Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis

Light Chain Amyloidosis: Where Are the Light Chains from and How They Play Their Pathogenic Role?

A conformational fingerprint for amyloidogenic light chains.

Structure and Energetic Basis of Overrepresented Λ Light Chain in Systemic Light Chain Amyloidosis Patients.

Conformational Differences in the Light Chain Constant Domain of Immunoglobulin G and Free Light Chain May Influence Proteolysis in AL Amyloidosis

Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue

Internalisation of immunoglobulin light chains by cardiomyocytes in AL amyloidosis: what can biopsies tell us?

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics

A mouse model of cardiac AL amyloidosis unveils mechanisms of tissue accumulation and toxicity of amyloid fibrils

The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or Without Coexistent Multiple Myeloma.

Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis

Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates

Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy

Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma

Immunophenotypic Analysis of Abnormal Plasma Cell Clones in Bone Marrow of Primary Systemic Light Chain Amyloidosis Patients

Immunotherapy in AL Amyloidosis

The Genomic Landscape of Plasma Cells in Systemic Light Chain Amyloidosis